RNA (Atrium Therapeutics) Total Liabilities: $58.26 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Total Liabilities?

Atrium Therapeutics RNA +0.16% 12 Total Liabilities is $58.26 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $58.26 Mil.

Atrium Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($64.69 Mil) to Dec. 2025 ($71.07 Mil) but then declined from Dec. 2025 ($71.07 Mil) to Mar. 2026 ($58.26 Mil).

Atrium Therapeutics's annual Total Liabilities declined from Dec. 2023 ($80.91 Mil) to Dec. 2024 ($68.29 Mil) but then increased from Dec. 2024 ($68.29 Mil) to Dec. 2025 ($71.07 Mil).

Atrium Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Total Liabilities Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
80.91 68.29 71.07

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 68.29 0.00 64.69 71.07 58.26
RNA
12GF Score
Atrium Therapeutics Inc RNA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Atrium Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.801+(0+0.574
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+28.691+0+0)
=71.07

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=278.353-207.287
=71.07

Atrium Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.905+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+36.351+0+0)
=58.26

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=292.36-234.104
=58.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $58.26 Mil mean?
Atrium Therapeutics (RNA) has a Total Liabilities of $58.26 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Total Liabilities too high?
Atrium Therapeutics' current Total Liabilities is $58.26 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Total Liabilities compare to RNAC and KROS?
Atrium Therapeutics' Total Liabilities of $58.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atrium Therapeutics and its competitors. Atrium Therapeutics's current Total Liabilities is $58.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Total Liabilities of $58.26 Mil. The current Total Liabilities is $58.26 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Total Liabilities is $58.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price